ArticlePharmacoEconomics2008

Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.

Simon Kreck et al.PubMed ↗Publisher ↗

No numbers read from the abstract.